share_log

Canaccord Genuity Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target

Benzinga ·  Mar 21 23:37

Canaccord Genuity analyst Whitney Ijem reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment